Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Corporates align with Purigen in series B round
Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Sense Photonics grasps $26m series A
Lidar technology developer Sense Photonics has emerged from stealth with $26m in series A funding from investors co-led by the UC-backed Congruent Ventures.
OncoMyx hits $25m
OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.
Lung Therapeutics clears $36m series C
UT Health's pulmonary drug treatment spinout Lung Therapeutics has raised a $36m series C, adding to at least $55m in previous funding from backers including UT Horizon Fund.
Azuri generates $26m
IP Group has backed Azuri Technologies, which markets pay-as-you-go solar-powered appliances to households in sub-Saharan Africa.
DiaMedCare helps Nexxiot reach next stage
Spun out of ETH Zurich, the logistics technology developer has secured $35.2m from DiaMedCare to roll out its upgraded supply chain-monitoring sensors.
GV illuminates Firefly’s series A round
Stanford-StartX Fund-backed Firefly has raised $30m from investors including GV, with the capital earmarked for expansion in regional markets including New York City.
Cardinal Analytx ticks off $23m series B
GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer based on Stanford research.

Other News

Pixie Dust cleans up with series B funding
Pixie Dust Technologies, which promotes university-derived technologies from Japan, has received $34.7m in a round that included KDDI, Kansai Electric Power, NEC, Toppan, Dai-ichi Life and Dentsu. pounces on $24m
CIC has returned to supply AI forecasting platform with series B capital and help take the company's overall funding to $39m.
Storm's series A continues to resound with investors
Cambridge's cancer drug spinout Storm Therapeutics convinced its existing investors to join new participant Seroba Life Sciences for a second extension that brought its series A total to $38.2m.
Ford joins Solid Power's series A
CU Boulder battery tech spinout Solid Power and Ford will collaborate on delivering a solid-state cell for electric vehicles using the spinout's production facility.
Algorithmia computes $25m series B
Osage University Partners, Gradient Ventures and Rakuten Ventures featured in machine learning software developer Algorithmia's latest round, which brought its total to $37.9m.
Neural Analytics cognises $22m
UCLA spinout Neural Analytics increased its total funding to $66m as it prepares for further testing of its robotically-assisted brain health monitoring platform.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg